Astellas Pharma Submits NDA For Avacincaptad Pegol For Geographic Atrophy In Japan
(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...
Pharmabiz8d
Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy
Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...
Morningstar9d
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
Learn more at www.astellas.com. 3 Colijn JM, Liefers B, Joachim N, et al. Enlargement of geographic atrophy from first diagnosis to end of life. JAMA Ophthalmol. 2021;139(7):743–750.
Nasdaq9d
Astellas Pharma Submits NDA For Avacincaptad Pegol For Geographic Atrophy In Japan
The company will also evaluate secondary to age-related macular degeneration in Japan. Geographic atrophy is ... currently approved outside the US or Australia. The NDA submission is based on ...